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A key characteristic of cancer cells is their increased proliferative capacity, which requires elevated levels of protein synthesis. The
process of protein synthesis involves the translation of codons within the mRNA coding sequence into a string of amino acids to
form a polypeptide chain. As most amino acids are encoded by multiple codons, the nucleotide sequence of a coding region can
vary dramatically without altering the polypeptide sequence of the encoded protein. Although mutations that do not alter the final
amino acid sequence are often thought of as silent/synonymous, these can still have dramatic effects on protein output. Because
each codon has a distinct translation elongation rate and can differentially impact mRNA stability, each codon has a different
degree of ‘optimality’ for protein synthesis. Recent data demonstrates that the codon preference of a transcriptome matches the
abundance of tRNAs within the cell and that this supply and demand between tRNAs and mRNAs varies between different cell
types. The largest observed distinction is between mRNAs encoding proteins associated with proliferation or differentiation.
Nevertheless, precisely how codon optimality and tRNA expression levels regulate cell fate decisions and their role in malignancy is
not fully understood. This review describes the current mechanistic understanding on codon optimality, its role in malignancy and
discusses the potential to target codon optimality therapeutically in the context of cancer.
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BACKGROUND
The gene expression signature in cancer is often significantly
altered, and this is often by elevated activity of oncogenic
transcription factors [1, 2]. However, changes at the level of
transcription do not always directly reflect the change in protein
level; [3] post-transcriptional regulation is also highly important in
shaping the cancer proteome. For example, transcript levels are also
altered in cancer at the level of mRNA stability [4, 5]. In addition,
rapid division and growth of the cancer cells requires increased
protein synthesis. To facilitate this, mRNA translation is often
dysregulated in tumour cells and the surrounding stroma [6].
Differential expression or covalent modification of a range of
translational regulators can enhance the survival and proliferation of
the tumour cell clone [7–9] and altered translation has been linked
with malignancy due to the upregulation of pro-oncogenic mRNAs
to promote proliferation and suppress apoptosis. Overall, due to the
increasing evidence for the importance of post-transcriptional
regulation in disease, translation is becoming a target area for
biomarker discovery and therapeutic intervention [10, 11].
It is the precise sequence composition of each individual
mRNA that allows for tight modulation of its translation and
stability. The untranslated regions (UTRs) of the mRNA are well-
known for their regulatory roles in post-transcriptional regulation
[12, 13]. Most of the research on translational regulation in
cancer has been centred on regulation exerted by elements
within the UTRs. For example within 5ʹUTRs there can be specific
sequence motifs such as terminal oligopyrmidine (TOP) motifs,
which are important for the mTOR signalling pathway regulation
in cancer [14] and highly structured regions in 5ʹUTRs,
particularly within oncogenic mRNAs, are reliant on eIF4A for
their translation [15–17]. A major example of 3ʹUTR regulation in
cancer is through miRNAs that themselves can act as oncogenes
or tumour suppressors [18]. Also, 3ʹUTR switching has been
noted in proliferating cells [19–23]. The use of alternative 3ʹUTRs
can lead to altered translation and/or stability of these messages
due to changes in the presence of 3ʹUTR regulatory sites [24]. The
significant influence of the coding sequence (CDS) in post-
transcriptional control of gene expression has come to light in
recent years, particularly differential codon usage, but this
regulation in the context of cancer is just beginning.
THE ROLE OF CODONS
The distinguishing feature of the CDS from the UTRs is the
presence of information that codes for the protein. A codon
dictates which amino acid is to be added to the growing
polypeptide during protein synthesis and for most amino acids
there are several codons which encode it - these are known as
synonymous codons. The existence of synonymous codons
allows for tight regulation of protein synthesis, in part, because
the translation elongation rates of synonymous codons are not
equal [25–27]. An additional layer of regulation pertains to the
surrounding codon context of an individual codon—often it is
doublets or stretches of certain codon combinations that
significantly impact the local translation rate [28]. Differential
translation elongation rates can serve multiple purposes beyond
just control of protein production levels; this includes: ribosome
pausing to allow for mRNA translocation and slowed localised
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elongation rates to allow for correct protein folding co-
translationally [29, 30]. Alternatively, prolonged ribosome
pausing at “non-optimal” codons can trigger mRNA destabilisa-
tion [31]. The details of these mechanisms will be discussed in a
later section.
TRNA SUPPLY AND DEMAND
A major factor contributing to the decoding rates of specific codons
is tRNA availability, both in terms of tRNA abundance and charging
with the specific amino acid (Fig. 1A). There are over 400 tRNA
genes across the human genome and these encode 46 different
tRNA isoacceptors (tRNAs which share the same anticodon but
differ in sequence elsewhere in the tRNA) [32]. tRNA isoacceptors
use cognate or wobble base pairing to decode 61 codons (Fig. 1B,
C) [32]. There are less anti-codons on tRNAs than there are codons,
in the majority of cases the first two nucleotides of a codon provide
the specificity for a given amino acid and follow standard Watson-
Crick base pairing to the tRNA anticodon. Then for certain codons
the tRNA ‘wobble position’ is used to recognise the codon, whereby
the 5ʹ end of the anticodon (hence 3rd nucleotide of the codon) can
still read codons with a non-cognate 3rd nucleotide. For example,
the tRNA with anticodon GGA can decode both the UCC and UCU
codon (Fig. 1B, C). In addition, modification to the first position of
the anticodon can enable additional wobble base-pair interactions.
For example, modification of adenosine to inosine (I) on the tRNA
increases the number of corresponding codons that can be
decoded to include a codon with not just U, but A or C at the
third position (Fig. 1B, C). The efficiencies of these base-pairings
differs with I:C being the most efficient and I:A the least [33] (Fig.
1C). Also, this wobble position of the tRNA is often subject to a
variety of modifications, which influence the ability to base pair
with different nucleotides [34, 35]. Codons requiring wobble base-
pairing take longer to decode and therefore have increased
ribosome dwell times [36, 37].
tRNAs are transcribed by RNA pol III and are processed to form a
mature tRNA with modified nucleotides and a 3ʹ CCA tail. The CCA
is required for the addition of an amino acid to the tRNA by an
aminoacyl-tRNA synthetase and for each specific amino acid there
is a different corresponding aminoacyl-tRNA synthetase. The
aminoacylated (charged) tRNAs are then delivered to the acceptor
site (A-site) of the elongating ribosome by eEF1A. If the tRNA
anticodon is complementary to the codon at the A-site the
polypeptide chain is extended and the ribosome translocates to
the next codon. In general, the expression levels of tRNAs (i.e.,
tRNA supply) are reflective of the transcriptome expressed—as
demonstrated by the fact that the most highly expressed genes
are enriched for the most abundantly expressed tRNAs [38].
Interestingly, several investigations have shown specific mRNA
and tRNA signatures associated with cellular state [39–41].
WHAT IS “CODON OPTIMALITY”?
Codon optimality is a term broadly used in reference to how the
identity of the codons within a given CDS regulate translation
elongation rates and mRNA stability and thus overall protein
production [42]. In principle, optimal codons are more rapidly
decoded meaning the ribosome has shorter dwell times on
optimal codons and their presence is associated with increased
mRNA stability (Fig. 2). Whereas codons are categorised as non-
optimal when the ribosome resides for longer at the codon due
to it taking longer for the corresponding tRNA to arrive at the
A-site and due to differences in decoding rates of specific tRNA
anticodon-codon interactions. ‘Rare’ codons are those which are
less frequently utilised with the transcriptome; the tRNAs that
recognise them also tend to be lowly expressed. Because of this,
rare codons are often non-optimal for protein synthesis,
particularly when present in clusters within the CDS. Overall,
translation elongation is faster across optimal codons (Fig. 2A),
and they are present in stable mRNAs resulting in association
with higher protein production from messages enriched for
optimal codons.
There are several metrics that can be used to quantify the impact
of codons on mRNA translation and stability including: the Codon
Adaptive Index (CAI) [43], the tRNA Adaptive Index (tAI) [44] and the
Codon Stabilisation Coefficient (CSC) [45]. CAI provides a measure
of codon bias in reference to the highly expressed genes, on the
assumption that highly expressed genes represent high demand for
certain tRNAs due to their elevated expression [43]. This has since
been adapted to the tAI which is based on the assumption that
tRNA gene copy numbers correlate with tRNA abundance and takes
into account the efficiency of the interaction between the codon
and the tRNA anticodon ‘wobble’ position [44, 46]. However, both
the CAI and tAI are static measures of codon optimality; the Codon
Stabilisation Coefficient (CSC) advances these metrics by account-
ing for mRNA stability dynamics. The CSC for each codon is the
Pearson correlation coefficient between the frequency of the codon
within the CDS of each mRNA and the mRNA half-live in a given
condition, across all mRNAs [45, 47]. For example, a positive CSC
would indicate that the frequency of a given codon is associated
with greater mRNA stability, whereas a negative CSC would indicate
the codon is associated with more rapid mRNA turnover. As the
mRNA half-lives determined can vary between cell type, cellular
state and because of the techniques used to measure it, the CSC
provides a way to relate the codon preference of a given CDS to its
translatability in a specific condition.
However, these metrics do not fully take into account the mRNA
abundance, given that mRNA expression levels are spread across a
large range this would be an additional important aspect to
incorporate to obtain more accurate measures of tRNA demand.
Also, these metrics tend to assume each codon has a distinct
optimality, but the codon context surrounding an individual
codon in a message has also been shown to be important for
differences in translation rates and mRNA stability [28]. CSCs have
been further utilised to try to identify stretches of non-optimal
codons within a message [47] and this is an important element to
take into consideration when investigating codon optimality.
Hence an “optimal” codon is one for which translation is
favoured, compared to a “non-optimal” codon that is less readily
decoded. A key determinant of this is tRNA supply; the
assumption being that “optimal” codons are those decoded by
the most abundant tRNAs [37]. The tRNA supply is also impacted
by the extent to which the expressed tRNAs are aminoacylated
and the ratio of cognate/near-cognate anticodons for decoding.
This supply is balanced by the demand for certain tRNAs within
the pool of mRNAs expressed that will impact overall availability of
a tRNA in the cell [48]. The translational environment is different
depending on the organism, cellular state and different stresses
[39, 49, 50]. Thus, codon optimality is not static, the ‘optimality’ of
a given codon is dependent on the supply of and demand for
translational resources which are condition dependent and
currently are difficult to precisely determine.
CODON USAGE WITHIN FUNCTIONALLY RELATED MRNAS
The codon usage of the human transcriptome has been naturally
selected for [51, 52] and synonymous codons are not used equally
across the transcriptome [53, 54]. In recent years, research has
sought to understand why such bias has evolved. It is now known
that functionally associated mRNAs share similar codon usage
patterns, particularly those that are co-expressed; [55, 56] and it
has been uncovered that distinct codon usage preferences allow
for translational regulation of specific gene groups [39, 57, 58].
Specifically, mRNAs that encode proteins that promote prolifera-
tion have a highly distinctive codon signature from mRNAs
encoding differentiation-promoting proteins [39]. Fig. 3
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recapitulates this key finding of Gingold et al. with the most up-to-
date gene ontology groups and the codons are coloured by the
3rd nucleotide. This shows in both mouse and human that the
synonymous codon usage preference of mRNAs associated with
the mitotic cell cycle is bias towards A/U-ending codons (Fig. 3 red
& purple), whereas pattern specifying mRNAs have a tendency to
contain G/C-ending codons (Fig. 3 blue & green). Several groups
have now observed mechanisms that exploit this distinctive
Fig. 1 Determinants of codon optimality. A The availability of tRNAs is a combination of their supply determined by tRNA gene expression
and aminoacylation of the tRNAs, and the demand within the expressed transcriptome for each tRNA. B tRNA availability combined with the
efficiency of the base-pairing between a given codon and anticodon provides a measure of the optimality of a given codon in a particular
cellular context. There are some C-ending codons that require A-to-I modification of the anticodon to be decoded. C Tables depict the types
of anticodon:codon base pairing that can decode each codon by either cognate, wobble or inosine interactions. Anticodons are in black and
are written 3ʹ to 5ʹ. Codons are coloured according to the 3rd nucleotide position and are written 5ʹ to 3ʹ. “>” is used to indicate differences in
efficiencies of decoding of inosine containing anticodons with codons that it can base-pair.
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codon signature to boost the synthesis of proliferative proteins
[39, 57, 59], as detailed in the later sections. This suggests that
codon usage can serve as a molecular switch to alter the
translational programme to meet the requirements of the cell.
In addition, in yeast, mRNAs encoding functionally related
proteins have been shown to have similar mRNA half-lives [45, 60].
Many of these groups contain mRNAs that possess a similar
percentage of optimal codons, for example: the glycolysis
pathway, pheromone response, tRNA modification and cytosolic
ribosomal proteins [45]. This suggests a mechanism whereby
codon optimality can be utilised to allow for coordinated
regulation of the stability of functionally related groups of mRNAs.
MECHANISMS THAT COORDINATE THE RESPONSE TO CODON
OPTIMALITY
The CDS codon composition and distribution have been high-
lighted as factors influencing translation rates and mRNA stability
in multiple organisms including: E.coli [38, 61], yeast
[31, 45, 62, 63], zebrafish [64, 65], mouse [57] and human cells
[58, 66–68]. At present the precise mechanisms involved in the
sensing of and response to codon optimality within a given mRNA
are not fully understood.
Codon optimality and mRNA stability
The global link between codon optimality and mRNA half-life was
first identified in yeast [45]. This study showed that substitution of
non-optimal codons to optimal codons in reporter constructs lead
to a large increase in mRNA stability [45]. Further research
suggests non-optimal codons lead to pausing of the ribosome due
to reduced translation elongation rates (Fig. 2A, B) [29]. In yeast it
has been suggested that if these pauses are not resolved they may
be “sensed”. Dhh1 [31], and Not5 [69] have both been suggested
as sensors of codon optimality and other factors may still be
discovered that couple this to the triggering of mRNA destabilisa-
tion. Dhh1 has been shown to sense non-optimal slowly translated
Fig. 2 Consequences of codon optimality differences. A Elongation rates are greater at optimal codons, leading to increased protein
synthesis rates. B Stretches of non-optimal codons can lead to a pile-up of paused ribosomes which can trigger recruitment of mRNA decay
factors. C Short stretches of non-optimal codons can also act to slow translation elongation rates in specific regions to provide time for correct
protein folding co-translationally.
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codons and then target these mRNAs for decay (Fig. 2B) [31]. The
impact of non-optimal codon stretches on mRNA stability was
greatest when they were located towards the 3ʹ end of the CDS.
This suggests not only the presence of non-optimal codons, but
their positioning within the CDS and the nature of the
surrounding codons are also important. Precisely how Dhh1
facilitates this is uncertain, but it has been proposed that Dhh1
interacts with the ribosome [31]. More recently, structural data has
shown that the Not5 subunit of the Ccr4-Not complex acts to
‘sense’ codon optimality via a direct interaction with the ribosome
[69]. More specifically, Not5 interacts with the E-site of the
ribosome that has an unoccupied A-site, presumably due to
pausing at non-optimal codons due to their slower decoding rate
[69]. The Ccr4-Not complex has also been implicated in codon-
mediated regulation of mRNAs in zebrafish [65] and DDX6 (the
human homologue of Dhh1) is known to interact with the Ccr4-
Not complex via the scaffold protein CNOT1 [70, 71], so perhaps
DDX6 acts in concert with the Ccr4-Not complex to link translation
elongation to altered mRNA stability.
In mammalian cells DDX6 is involved in directing the
translational repression of mRNAs enriched for A/U-ending codons
in p-bodies and regulates G/C-rich mRNAs at the level of mRNA
stability [72]. This suggests a link not only between codon
optimality and mRNA stability, but also translational repression
and mRNA storage. Exactly which codons are associated with
faster mRNA turnover varies across studies; [45, 68, 72, 73] these
differences may be due to the fact that what is an “optimal codon”
differs depending on the translational environment—as discussed
in the previous section. This concept is demonstrated in a study in
Drosophila which showed A/U-ending codons were associated
with faster mRNA destabilisation in non-neuronal cells, whereas in
the neuronal cells it was the G/C-ending codons that were
associated with more rapid mRNA decay [74].
Overall, it is clear there is much we still do not understand
about how the cell detects codon optimality and its downstream
consequences, but there are indicators that the Ccr4-Not complex
and its associated helicase DDX6 have a key role in these
mechanisms, whether it be by direct interaction with the stalled
ribosomes or by interaction with downstream effector proteins.
The importance of non-optimal codon location and context
within the CDS
An additional factor to consider is not only the presence of non-
optimal codons, but the positioning of these within the CDS.
Codons are not used equally across the CDS [75]. Research shows
that across multiple organisms, from E.coli to human that the G/C
content (and hence codon usage) decreases after the first 25
codons [76]. As detailed in the previous section, reporter assays
have shown positional dependency of non-optimal codons on
Dhh1-mediated regulation of mRNA half-life [31]. However,
although a further global investigation of mRNA half-lives across
the yeast transcriptome showed that ribosome pausing occurs at
non-optimal codons, it did not observe a link between the
position of non-optimal codons within the CDS and mRNA
stability [47]. So, whether increased non-optimal codon fre-
quency is sufficient to cause mRNA half-life differences, or if
position-dependent effects on mRNA stability are mRNA specific
is still unclear.
The surrounding sequence context of an individual non-optimal
codon has been identified as a contributing factor to the extent to
which non-optimal codons affect translation elongation rate and
mRNA stability [28]. It has been shown that stretches of non-
optimal codons can be particularly inhibitory to translation [47].
Studies have shown a role for inhibitory codon pairs in the
regulation of translation and mRNA stability [28, 62, 77]. These
pairs consist of non-optimal codons where at least one relies on
wobble base-pairing with the tRNA anticodon [28]. In order to be
inhibitory, the pair must be consecutive on the CDS and the order
of the codons within the pair is also important [28]. In addition,
with the specific example of ZEB2 mRNA, stretches of non-optimal
codons were shown to impact protein synthesis [78].
While the presence of non-optimal codons can lead to a global
reduction in the elongation rate of a message, the purpose can
also be to only reduce translation elongation speed in a specific
region of the CDS. This serves as an important role in terms of
protein structure by ensuring correct protein folding co-
translationally and therefore allowing functional protein produc-
tion [79–81]. Stretches of “slow” codons reduce the local
translation elongation rate to provide sufficient time for accurate
protein folding (Fig. 2C) [82, 83]. Substitution to “faster”
synonymous codons has been shown to increase the likelihood
of misfolded proteins, alter protein conformation or lead to
protein aggregates [81, 84]. Whether there is a connection
between slowed elongation rates for protein folding and
ribosome pausing that can trigger mRNA destabilisation pathways
has not been investigated.
Codon optimality interactions with other regulatory features
It is unknown how codon usage interacts with other translational
regulatory factors. A recent study demonstrated that miR-430 can
promote destabilisation of targets rich in optimal codons [85],
suggesting the global impact of codon optimality can be fine-
tuned by other additional regulatory mechanisms. miRNAs are
often dysregulated in cancer so further investigation of the
interplay between different regulators of translation with codon
usage could be an interesting area of investigation in the future.
Fig. 3 Codon usage differences in proliferation. Synonymous codon usage preferences for mRNAs associated with the GO term: “pattern
specification” and ‘mitotic cell cycle’ for mouse (245 and 653 mRNAs respectively) and human (418 and 900 mRNAs respectively). Conducted
in a similar manner to Gingold et al. 2014, but with the most recent gene ontology annotation obtained using the R package GO.db. Colours
indicate the nucleotide at the 3rd position of the codon and the single letter code is used to indicate the corresponding amino acids.
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What about secondary structure?
As non-optimal codons are predominantly described as those with
A/U at the wobble position, it should be noted that this changes
the propensity for secondary structure within the coding
sequence. It is very difficult to unpick differences in translation
rate for these codons due to secondary structure or tRNA
availability and it could well be a combined effect of both. Work
from yeast and E.coli proposes that secondary structure in
conjunction with tRNA abundance balances translation elongation
rates of specific codons [86], in that secondary structure can result
in slower translation, but this is overcome by these structured
regions often being composed of optimal codons decoded by
highly abundant tRNAs. In addition, reporter assays in which both
the codon optimality and the propensity of the mRNA to form
structure were manipulated demonstrated that increased struc-
ture formation in mRNAs with optimal codon usage further
stabilised the mRNA [87]. The G/C content of a message also
regulates its transcription [88, 89]. So perhaps differences in codon
optimality also play a role in determining whether a given
message is more highly regulated at the transcriptional and/or
translational level.
Use of codon optimality to regulate the synthesis of proliferation-
promoting proteins. The mRNA and tRNA pools expressed vary
across tissues [48, 50, 90]. The tissue-specific mRNA pools differ in
their codon usage and these differences have been shown to be
conserved between human and mouse [91]. The codon usage
preference of tissue-specific mRNAs has been shown to impact
translational efficiency by their optimality for the corresponding
tRNA availability in the tissue [92], in that their codon usage is
most optimal for translation in the tissue they are predominantly
expressed in.
The most abundant mRNAs in the cell are enriched in codons
that require decoding by the most abundant cognate tRNAs thus
ensuring optimal protein synthesis. It has been suggested that in
certain cases the opposite is also true, in that certain mRNAs have
evolved to specifically have poorly optimised codon usage for
‘normal’ conditions, hence they are poorly expressed when not
required by the cell [93]. For example, some circadian clock genes
have a greater prevalence of non-optimal codons [55, 94] and cell
cycle genes, particularly those that oscillate, are enriched in non-
optimal codons, with genes that are expressed in different cell
cycle phases showing distinct codon usage [57, 95]. In addition,
general levels of tRNAs and tRNA charging enzymes are highest in
the G2/M phase, when those proteins most enriched in non-
optimal codons are expressed [95]. By sharing a distinct codon
preference, groups of genes can be up or downregulated when
required, such that under normal conditions they are kept in a
translationally repressed state but could be translationally
upregulated upon the appropriate signals [93].
Regulation of “proliferative tRNAs”
There are multiple hypotheses for how proliferation-associated
protein expression is specifically increased. Gingold et al. observe
specific upregulation of proliferative mRNAs and their correspond-
ing tRNA supply with large changes in histone modifications
around specific tRNA genes, proposing a transcriptional program
to coordinate an increase in proliferative mRNA and tRNA
expression [39]. Of note, while proliferative mRNAs (enriched for
A/U-ending codons) were upregulated in both non-cancerous and
cancerous proliferative samples, the mRNA transcriptomes overall
more closely clustered based on cell/tissue type as opposed to
proliferative status of the samples. This study classified tRNAs as
either proliferation- or differentiation-specific tRNAs, and these
groupings were highly similar in both cancerous and non-
cancerous settings [39]. This model of specific upregulation of
proliferative tRNAs to boost translation elongation rates at specific
codons enriched in the mRNAs encoding proliferation associated
proteins (Fig. 4) is further supported by data showing that the
tRNA-ome expressed is reflective of the proliferative status of
tissues [48]. Subsequent work has shown that by targeting
individual tRNA families with the CRISPR-Cas9 system, most of
the identified proliferation-promoting tRNAs were essential in
rapidly dividing cells, with the tRNAs associated with differentia-
tion showing higher essentiality in cells with a slower doubling
time [96]. Although these differences could be assigned to the
proliferative state of the cell, it seemed that the cellular origin was
also an important factor [96].
An alternative model has been proposed by Guimaraes et al.
that rather than specific upregulation of ‘proliferative tRNAs’, there
is a global increase in all tRNA levels in proliferative conditions
(Fig. 4), due to the overall boost in translation required in highly
Fig. 4 tRNA changes in proliferation. There are several models proposed as to how the translational upregulation of mRNAs preferentially
expressed in proliferation occurs. These include a specific increase in the tRNAs that decode A/U-ending codons, a global increase in tRNA
expression to overcome limiting elongation rates at non-optimal codons and increased mcm5s2 U34 modification at the wobble position to
increase the elongation rates at specific A-ending codons: CAA, AAA, GAA.
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proliferative cells. This model is proposed because they found no
differential tRNA expression between cells grown in 10% serum
compared with 1% but did observe increased translational
efficiency on mRNAs enriched in A/U-ending codons [57]. A
global increase in tRNA levels then overcomes the reduced
elongation rates of proliferation specific mRNAs that are limited by
their enrichment for A/U-ending codons that have ‘rare’ tRNA
anticodons relative to the general tRNA supply [57].
It is probable that each study has revealed a pathway that cells
can use to boost protein synthesis from mRNAs that are non-
optimal for translation under normal conditions. The commonality
between the models is that tRNA supply for decoding of non-
optimal codons is a limiting factor to be overcome in order to
facilitate the increased protein synthesis of proliferation-specific
mRNAs. While the increased mRNA-level of these proliferation-
specific mRNAs may in part be explained by increased transcrip-
tion, the increased translation elongation rates at these A/U-
ending codons in proliferative conditions also likely stabilises
these proliferative mRNAs.
TRNAS IN CANCER
Increased proliferation requires increased protein synthesis to
facilitate this boost in mRNA translation, the tRNA supply needs to
also increase – this can be global or specific upregulation of tRNAs.
tRNAs are transcribed by RNA polymerase III and increased RNA Pol
III activity has long been associated with cancer [97], as are
elevated tRNA levels [98]. This is in part due to key oncogenes such
as MYC, or pathways that are dysregulated in cancer like
mTORC1 signalling, impacting on RNA pol III and consequently
altering tRNA biogenesis [99, 100]. In combination an upregulation
of tRNA synthetases, tRNA modification enzymes and other
translation factors often occurs in cancer which together support
the translational enhancement required for rapid proliferation [41].
Altered tRNA-ome
The first attempt at exploring tRNA expression in cancer tissue
showed that both nuclear and mitochondrial encoded tRNAs were
upregulated both globally and specifically in tumour compared to
normal breast tissue [101]. The relative differential expression of
tRNA levels was observed both at the amino acid and isoacceptor
level. tRNAs encoding both polar and charged amino acids
showed the highest relative increase in cancer tissue [101]. They
also compared the tRNA profiles to the codon usage of either
cancer specific, cell line specific or house-keeping genes and
found that only the cancer specific genes were enriched in the
codons decoded by the tRNAs with greater expression in the
cancer tissues. A global upregulation of tRNAs in cancerous cells
was also found by Mahlab et al., but this study did not identify any
relative changes in specific tRNAs [98].
There are two studies that have utilised The Cancer Genome
Atlas (TCGA) database to assess tRNA expression for many
samples across cancer types. These identify several tRNAs with
altered expression in tumorigenesis [41, 48]. Between paired
normal and tumour samples the greatest differences in tRNA
expression at the amino acid level were for tRNAs that decode
arginine, cysteine and valine [41]. This study also noted that
certain tRNAs were upregulated in some cancers and down-
regulated in others [41], indicating cancer specific alterations, yet
most cancers showed a greater number of upregulated tRNAs
than downregulated tRNAs, suggesting that overall tRNA expres-
sion is increased in cancer. High tRNA-ArgUCG and tRNA-ArgUCU
expression were equated with poor survival in kidney renal clear
cell carcinoma, whereas it was low levels of tRNA-ThrUGG and
tRNA-ProUGU associated with poor survival [41].
Increased supply of specific tRNAs has also been demonstrated
to facilitate metastasis [40]. Overexpression of both tRNA-GluUUC
and and tRNA-ArgCCG is observed in metastatic breast cancer cell
lines compared to their non-metastatic parental lines. By either
overexpressing these tRNAs in the non-metastatic lines or knocking
them down in the metastatic cell lines, this study showed that the
expression levels of these tRNAs is correlated with the metastatic
potential [40]. EXOSC2 and GRIPAP1 were identified as key
downstream targets of tRNA-GluUUC and their increased expression,
at least in part, explains the increased metastatic potential following
the upregulation of tRNA-GluUUC [40].
A lack of correlation between cellular state and differential tRNA
expression has been noted albeit using an indirect measurement
of tRNA levels [102], however the ability of a global upregulation
of tRNA expression to specifically impact the translation rates of a
subset of mRNAs has also been observed [57]. In addition, it is not
just changes in tRNA expression, but also tRNA modification
differences that have been observed in cancer [103]. Differences in
tRNA modification profiles have been observed between paired
fast and slow growing cells and between endometrial cancer
tissue and their adjacent normal tissues, with most modifications
increasing in the more proliferative cells [104]. In addition,
adenosine to inosine editing at the wobble position (A34I) of
tRNAs was shown to be higher in self-renewing stem cells
compared with differentiating cells [105]. This led to increased
decoding of NNC and NNU codons that utilise A34I edited tRNAs.
However, whether this leads to increased protein expression of
mRNAs enriched for these codons remains to be shown.
Furthermore, the RNA methyltransferase NSUN2 has been shown
to be associated with metastatic progression in breast cancer
[106] and poor survival in Head and Neck Squamous Carcinoma
[107]. However increased modification is not always the case,
eighteen types of tRNA modifications and seven tRNA-modifying
genes are downregulated in non-small lung cancer [108] and
human tRNA methyltransferase 9-like (hTRM9L), which catalyses
tRNA wobble base modifications has been shown to be down-
regulated in several cancers [109].
The mcm5s2 modification of U34 promotes decoding of AAA,
GAA, and CAA codons and is carried out by a cascade of enzymes,
including the Elongator complex [103]. Several components of the
elongator complex have been shown to be upregulated in breast
cancer tissue [110] and melanoma [111]. Also, ablation of the
catalytic subunit elp3, reduced tumour growth in wnt dependent
intestinal tumours [112] and impaired metastasis in an invasive
mouse model of breast cancer [110] and re-sensitised resistant
BRAFV600E melanoma cells to a BRAFV600E inhibitor [111]. These
studies provide evidence that U34 modification of tRNAs is
required for the decoding of specific mRNAs involved in tumour
initiation, invasion and therapeutic resistance, such as SOX9 [112],
DEK [110] and HIF1α [111] and HNRNPQ [113], due to the
enrichment of these mRNAs in AAA, GAA, and CAA codons.
mcm5s2U34 modifications therefore provide a mechanism to
increase the decoding rate of mRNAs that are enriched in these
specific A-ending codons, that are often associated with
proliferative mRNAs, without increasing the abundance of overall
or specific tRNAs (Fig. 4). In addition, transcriptome changes that
occur following ERα depletion are translationally offset in mRNAs
specifically enriched for codons that can utilise mcm5s2U34
modification decoding and ERα regulates the expression of
enzymes involved in mcm5s2U34 modification in prostate and
breast cancer cells [114]. This suggests the regulation of codon
optimality and thus decoding rates by mcm5s2U34 modification
may also play an important role in translational buffering allowing
protein levels to be maintained despite transcriptional changes.
tRNAiMet
Of all tRNAs, the one unique tRNA, which is presumably equally
required by all mRNAs is of course the initiator methione tRNAi
Met.
Upregulation of tRNAi
Met, but not tRNAe
Met has been observed in
proliferative samples [39] and overexpression of tRNAi
Met in non-
transformed breast cell lines lead to increased cellular metabolism
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and proliferation [101]. tRNAi
Met overexpression also altered the
expression of additional tRNAs, suggesting a possible feedback
mechanism between tRNA levels and tRNA transcription [101],
whether this feedback is more widely applicable to overexpression
of other specific tRNAs is unknown. A more specific role for
tRNAi
Met has also been identified in promoting tumorigenesis
through enhancing the cancer associated secretome, resulting in
increased extracellular matrix deposition [115]. This is further
supported by ribosome profiling data showing the specific
translational upregulation of extracellular matrix proteins in
hepatocellular carcinoma [116].
Overall, an increase in tRNAi
Met could help overcome the main
rate-limiting step in protein synthesis: translation initiation, which
could explain why there is a global boost in translation following
tRNAi
Met overexpression. In these circumstances it could be that
the influence of codon optimality on translation rates of certain
mRNAs increases as the rate limiting step shifts from translation
initiation to translation elongation and hence the tRNA supply and
demand become of even greater importance than in a ‘normal’
situation.
ONCOGENES/TUMOUR SUPPRESSOR GENES
One way in which oncogenes support rapid cell growth is by
upregulating the expression of components of the translational
machinery to enable increased levels of protein synthesis. For
example, C-MYC increases the transcription of ribosomal proteins,
ribosomal RNA, and mRNA cap binding complex components
[117–119]. Both the oncogene C-MYC and the tumour suppres-
sor’s p53 and Rb bind TFIIIB activating and repressing RNA
polymerase III transcription respectively [99, 117, 120]. Therefore,
dysregulation of these protein leads to altered tRNA supply in
cancer which may not only be on a total tRNA-level, but also
changes in specific tRNA levels [121]. As there are often major
transcriptional changes associated with oncogene/tumour sup-
pressor expression changes in cancer it is likely they also alter the
tRNA demand by re-sculpting the transcriptome expressed.
Synonymous mutations
Synonymous mutations were once considered silent as they do
not alter the amino acid sequence of the protein. However, it has
become clear that synonymous mutations can still impact protein
synthesis and function [94, 122]. A large-scale study of mutations
across cancers [123] identified 23.4% (659,154 mutations) of pan-
cancer point mutations as synonymous and 26.8% of these were
seen consistently across tumour types. This study showed that
these recurrent synonymous mutations are more prevalent in
tumours that have a lower mutational load suggesting they are
particularly specific mutations. Studies have shown that the most
frequent form of synonymous mutation is C/G - > T/A [123, 124]. A
recent study using ribosome profiling data from patient liver
cancer samples identifies synonymous mutations that change
codon optimality significantly impact translation rates at these
specific codons [116, 125]. Synonymous mutations to G/C led to a
reduction in A-site ribosome occupancy at these specific positions
when comparing the occupancy on the wild-type allele to the
mutated allele within tumour samples, whereas for changes to A/
U there was an increase in A-site ribosome occupancy [125].
Whether this is sufficient to alter protein levels was not examined,
but this does demonstrate how single synonymous mutations can
directly impact local translation elongation rates.
Li et al. showed oncogenes had a greater translational efficiency
and tumour suppressors lower translational efficiency in tumour
samples compared to normal tissue. This group together with
others have observed an enrichment for synonymous mutations
to optimal codons in oncogenes, and to non-optimal codons
within tumour suppressors genes [125–127]. Suggesting these
mutations could serve to increase the synthesis of oncogenic
proteins or decrease the synthesis of tumour suppressors thus
driving the initiation of cancer development. Interestingly, the
prevalence of synonymous mutations in particular oncogenes
varies across tissues [123]. Given that the tRNA-ome also varies
across tissues [90] it may be that certain synonymous mutations
are more influential on cancer development depending on the cell
origin. The localisation of synonymous mutations within the CDS
of oncogenes is not random, in that they are more prevalent in
specific regions [123]. Synonymous (and missense) mutations are
more likely to occur in conserved regions which is likely why they
can be so impactful on protein function.
Codon signatures
While it is clear that, in general, mRNAs associated with
proliferation have a distinct codon usage from mRNAs associated
with differentiation, what does this look like at the individual
mRNA level within oncogenes and tumour suppressors?
One of the best studied oncogene families in terms of codon
optimality is the RAS family of small GTPases, composed of KRAS,
HRAS and NRAS. Despite these proteins sharing ~85% identity at
the amino acid level, they share only ~15% codon identity, with
KRAS being enriched in proliferation associated A/U ending
codons, often referred to as “rare” codons, and HRAS being
enriched in the more commonly found G/C ending codons and
NRAS being intermediate [128]. The enrichment of rare codons in
KRAS has been shown to limit its translation, which is relieved
when these codons were converted to more common G/C ending
codons in cultured mammalian cells [128–130]. In addition to
altered translation rates, the codon usage of KRAS affected its
mRNA abundance, whether this occurs at the level of transcription
[129] or mRNA stability [130] is debated.
The expression level of RAS has previously been shown to
impact tumorigenesis, in that high levels lead to senescence,
whereas lower levels result in tumour development [131].
Interestingly, after heterozygous conversion of 27 of the KRAS
rare codons to more optimal codons, KRAS levels are elevated and
this is accompanied by reduced tumour formation and senes-
cence induction [132]. Thus, suggesting that the increased
prevalence of non-optimal codons in KRAS functions to maintain
its low expression levels and therefore prevent the induction of
cellular senescence. However, given higher expression of onco-
genic KRAS drives increased tumour growth in transformed cells
[128], it seems that a mechanism to increase its protein synthesis
would be required once the barrier of oncogene induced
senescence is overcome. One mechanism could be that the
altered tRNA-ome in proliferative conditions allows for faster
decoding of A/U-ending codons, which could increase KRAS
translation and/or mRNA stability. In support of this, reporter
studies have shown that the wild-type KRAS was upregulated at
both the protein and RNA level more so than a codon optimised
KRAS reporter in fed vs starved conditions [130].
The utilisation of synonymous codon usage to differentially
regulate the expression levels of oncogenes between normal and
proliferative conditions, could be a more widespread mechanism
by which oncogenes drive tumorigenesis. Data to support this
includes the observation that several cancer-related protein
families have high amino acid identity but the most frequently
mutated member in cancer is most enriched in proliferation
associated codons [130].
CONCLUSIONS AND FUTURE PERSPECTIVES
The presence of synonymous codons within the genetic code has
enabled a mechanism to develop which allows regulation at the
mRNA decoding and stability level, whether it is to optimise
translation of essential proteins, regulate localised translation rates
to ensure correct co-translational protein folding or to up/down
regulate specific gene sets when required. The fact that
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elongation can be directly sensed in this manner, means that
elongation rates will contribute to the overall protein expression,
even for the majority of mRNAs in which initiation is the rate
limiting step of translation. However, there remains inconsisten-
cies in our understanding of the exact interplay between tRNA
levels, tRNA modification, elongation rates and codon optimality,
particularly in higher eukaryotes. Also, there is still much to be
understood about how codon optimality interacts with other
factors to regulate mRNA stability and protein output. For
example, although loss of wobble U34 modification leads to the
specific elongation block at NAA codons, this is not sufficient for a
reduction in protein expression levels. Rather, those proteins that
decrease in expression also possess a pentameric hydrophilic
motif which causes the synthesised proteins to aggregate and be
subsequently degraded [133]. One possible explanation for this
could be that altered elongation rates at NAA codons lead to
protein misfolding co-translationally and thus expose this motif.
Codon optimality is dynamic, and dependent on a multitude of
factors that shape the translational environment. Specific func-
tionally related gene sets have acquired a similar pattern of codon
usage that is non-optimal for ‘normal’ conditions, but by increased
expression of tRNA subsets or alterations to tRNA modification
pathways, the optimality of these codons can effectively be
switched on. This leads to specific codons being optimal for mRNA
translation/stability depending on the cellular state, cell cycle
phase and other influences such as stress.
Until recently, tRNAs have been inherently difficult to sequence
because they are highly structured and heavily modified, but now
methods have been developed to overcome these limitations and
allow us to ascertain the tRNA-ome globally, enabling the
interrogation of differential tRNA pools between conditions. To
overcome the major tRNA modifications that would otherwise
block the reverse transcription step of library preparation, these
modifications are typically either removed, such as by demethyla-
tion with AlkB treatment [134] or alternatively a highly processive
reverse transcriptase, named TGIRT, is used that can read-through
modifications with a high error rate, to provide full-length tRNA
reads regardless of tRNA modification status [135, 136]. Further
improvements also include the use of custom ligation methods to
add sequencing adapters despite problems due to tRNA structure
and some methods also assess the tRNA charging [137].As
described in the earlier sections, these methods have enabled
the identification of differential tRNA expression in proliferation
compared to differentiation. Whether it is indeed specific
upregulation of the proliferative tRNAs or global upregulation,
either would lead to increased expression of proliferative mRNAs.
In the future, it might be possible to therapeutically manipulate
the tRNA pools to reduce proliferation-specific protein synthesis
and therefore halt tumour development. Whichever mechanism is
at play there are still unanswered questions about the precise
details – what factors are driving the increase in proliferative
mRNA and tRNA expression? What factors direct upregulation of a
specific subset of tRNAs? In addition, there is still much to
understand about the regulation of tRNA modifications and how
this impacts codon optimality in a condition specific manner.
Moreover, most tRNA studies have assessed the tRNA-level, but do
not always identify the charging status of the tRNA, so there may
be further regulation at the level of tRNA charging.
Developments in next generation sequencing techniques not
only allow us to identify the translating mRNA population
(polysome profiling), but now enable nucleotide resolution of
ribosome occupancy for each transcript (ribosome profiling [138],)
meaning that ribosome residency at each codon of a message can
be examined. This could be used in combination with improved
tRNA-seq methods to accurately determine changes in tRNA
abundance and charging. These complementary techniques
provide a very powerful approach in which to dissect the
underlying mechanisms at play and hence provide a global view
of the dynamics of codon optimality differences in cancer.
However, it is important to note that while ribosome occupancy
generally correlates with protein synthesis rates, its increase can
also indicate ribosome stalls and slowed elongation. Therefore,
given that changes in tRNA levels and/or codon optimality will lead
to changes in the rate of elongation, an improved approach is to
combine ribosome profiling with pulsed SILAC [139] to provide a
direct measure of changes in protein synthesis rate. This could also
be used to identify potential pause sites that are resolved or
augmented in different conditions and could be used to investigate
the regulation that may be occurring at specific rare/non-optimal
codons in mRNAs encoding oncogenes/tumour suppressors. Thus,
we can now aim to understand the role of codons in cancer at
nucleotide resolution allowing us to study the dysregulation of
translation in key oncogene/tumour suppressor mouse models.
Since increased cell proliferation is such a key characteristic of
cancer, it will be interesting to explore how the distinguishing
proliferative codon usage signature can be utilised in the specific
targeting of cancer cells and whether specific tRNAs or indeed
amino acids could be targeted to exploit any potential vulner-
abilities. Furthermore, given that different tissues have different
codon usage patterns in the specific transcriptome expressed, the
fact that viruses adapt their codon usage to the tissue they infect,
and mRNA-based therapeutics are a possible future treatment for
cancer, understanding codon optimality in cancer could be
important in the design of potential future mRNA-based
therapeutics to maximise expression in the target cell populations.
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